Skip Navigation LinksHome > February 1995 - Volume 8 - Issue 2 > Phase I/II Evaluation of Nevirapine Alone and in Combination...
Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology:

Phase I/II Evaluation of Nevirapine Alone and in Combination with Zidovudine for Infection with Human Immunodeficiency Virus.

Cheeseman, Sarah H.; Havlir, Diane; McLaughlin, Margaret M.; Greenough, Thomas C.; Sullivan, John L.; Hall, David; Hattox, Susan E.; Spector, Stephen A.; Stein, Daniel S.; Myers, Maureen; Richman, Douglas D.

Collapse Box


Summary: In these Phase I/II open-label clinical trials, 62 persons with human immunodeficiency virus type 1 (HIV-1) infection and CD4+ cell counts <=400/mm3 received nevirapine at doses of 12.5, 50, and 200 mg/day, alone or in combination with zidovudine, 200 mg q8h. Nevirapine was well tolerated in the doses tested. Mean steady-state trough levels were 0.23, 1.1, and 1.9 [mu]g/ml for the 12.5, 50, and 200 mg/day doses, respectively. Early suppression of p24 antigen levels and increase in CD4+ cell count were reversed following rapid emergence of virus less susceptible to nevirapine. Resistant strains were isolated from all participants by 8 weeks. Nevertheless, reduction of p24 arifigen levels to <=50% of baseline values persisted for 12 weeks or more in four of seven persons who received 200 mg nevirapine/day in combination with zidovudine: these individuals had been antigenemic on long-term zidovudine therapy. This study demonstrates a direct relationship between drug resistance and effects on surrogate markers in HIV-1 infection.

(C) Lippincott-Raven Publishers.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.